BioGeneration Ventures IV fund (BGV IV)

https://www.biogenerationventures.com

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over €400 million of funds, and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV is the early-stage focused platform partner of Forbion, a leading European life sciences venture capital fund with €3 billion in capital under management, and is based in Naarden, The Netherlands. For more information, please visit: http://www.biogenerationventures.com. The Fund V received an investment from the European Investment Fund, notably as part of the Venture Centre of Excellence initiative supported by the Health Compartment of the Sustainable Development Umbrella Fund, with the financial backing of the European Union under the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. *

	Start	2021-01-07 fund closing
	Group	BioGeneration Ventures B.V. (BGV)
	Predecessor	BioGeneration Ventures III fund (BGV III)
	Successor	BioGeneration Ventures V fund (BGV V)
	Industry	venture capital
	Industry 2	BIOTECH
	Person	van Wezel, Edward (BioGeneration Ventures 201710 Managing Partner before Macrozyme 200511 CEO)

	Region	Naarden
	Country	Netherlands
	City	1411 DC Naarden
	Tel	+31-35-699-3000
		Address record changed: 2021-01-19

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	140,000,000 (fund size at closing (2021) 2021-01-07)

		* Document for »About Section«: BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden.

		Record changed: 2024-02-12